Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 79

Sort by

Sort Order Select

Journal Articles

DNA polymerase θ protects leukemia cells from metabolically induced DNA damage

Blood (2023) 141 (19): 2372–2389.

https://doi.org/10.1182/blood.2022018428

Published: 2023

Includes: Supplemental data

Journal Articles

DNA Polymerase Theta Protects Leukemia Cells from Metabolic-Induced DNA Damage

Blood (2022) 140 (Supplement 1): 2972–2974.

https://doi.org/10.1182/blood-2022-156458

Published: 2022

Journal Articles

Sirolimus Results in Similar Outcomes to Tacrolimus for Gvhd Prophylaxis after Haploidentical Peripheral Blood Stem Cell Transplantation with Post-Transplant Cyclophosphamide

Blood (2022) 140 (Supplement 1): 7638–7640.

https://doi.org/10.1182/blood-2022-168400

Published: 2022

Journal Articles

Patients with AML Who Achieve Long Term Complete Remission Do Not Have a Normal Life Expectancy When Compared to the General Population. Analysis of 3,012 Patients Enrolled on 9 Consecutive ECOG-ACRIN Trials

Chezi Ganzel, Kevin Roopcharan, Zhuoxin Sun, Jacob M. Rowe, Hugo F Fernandez, Elisabeth M. Paietta, Selina M. Luger, Hillard M Lazarus, Larry D Cripe, Dan Douer, Peter H. Wiernik, Martin S. Tallman, Mark R. Litzow

Blood (2021) 138 (Supplement 1): 690.

https://doi.org/10.1182/blood-2021-149208

Published: 2021

Journal Articles

Phase II Trial of Eprenetapopt (APR-246) in Combination with Azacitidine (AZA) As Maintenance Therapy for TP53 Mutated AML or MDS Following Allogeneic Stem Cell Transplantation (SCT)

Asmita Mishra, Roni Tamari, Amy E. DeZern, Michael T. Byrne, Mahasweta Gooptu, Yi-Bin Chen, H. Joachim Deeg, Phillip Gallacher, Anders Wennborg, Denice Kaylor Hickman, Eyal C. Attar, Hugo F. Fernandez

Blood (2021) 138 (Supplement 1): 409.

https://doi.org/10.1182/blood-2021-147962

Published: 2021

Journal Articles

TET2 and DNMT3A Mutations Exert Divergent Effects on DNA Repair and Sensitivity of Leukemia Cells to PARP Inhibitors

Blood (2020) 136 (Supplement 1): 4.

https://doi.org/10.1182/blood-2020-137658

Published: 2020

Journal Articles

Outcomes of Patients with Relapsed or Refractory Acute Myeloid Leukemia Receiving Hypomethylating Agent and Venetoclax

Hannah Asghari, MD BS, Dasom Lee, MD, Yehuda E. Deutsch, MD, Onyee Chan, MD, Najla Al Ali, M.Sc, Stephanie Boisclair, MD, Amanda Brahim, PharmD, Eric Padron, MD, Andrew T Kuykendall, MD, Alan F. List, MD, Hugo F. Fernandez, MD, Jeffrey E. Lancet, MD, David A Sallman, MD, Rami S. Komrokji, MD, Kendra L. Sweet, MD, Chetasi Talati, MD

Blood (2019) 134 (Supplement_1): 1357.

https://doi.org/10.1182/blood-2019-128958

Published: 2019

Journal Articles

Hypomethylating Agent and Venetoclax Combination Therapy Yields Superior Outcomes When Compared to Hypomethylating Agent Monotherapy in Patients ≥70 Years with Acute Myeloid Leukemia

Yumeng Zhang, MD, Hannah H Asghari, MD, Onyee Chan, MD, Dasom Lee, MD, Martine Extermann, MD, Najla Al Ali, M.Sc, Yehuda E. Deutsch, MD, Eric Padron, MD, Andrew T Kuykendall, MD, Alan F. List, MD, Hugo F. Fernandez, MD, Jeffrey E. Lancet, MD, Rami S. Komrokji, MD, David A Sallman, MD, Chetasi Talati, MD, Kendra L. Sweet, MD

Blood (2019) 134 (Supplement_1): 1368.

https://doi.org/10.1182/blood-2019-127772

Published: 2019

Journal Articles

Comparison of Overall Responses after Standard Induction with High Dose Daunorubicin Versus Standard Dose Daunorubicin with Gemtuzumab Ozogamicin in Favorable Risk Acute Myeloid Leukemia

Chetasi Talati, MD, Ryan J Caddell, PharmD, BCOP, Katherine Tobon, PharmD, Rami S. Komrokji, MD, Andrew T Kuykendall, MD, Eric Padron, MD, Hugo F. Fernandez, MD, Alan F. List, MD, David A Sallman, MD, Kendra L. Sweet, MD, Jeffrey E. Lancet, MD

Blood (2019) 134 (Supplement_1): 2636.

https://doi.org/10.1182/blood-2019-129166

Published: 2019

Journal Articles

CPX-351 As Induction Chemotherapy Yields Similar Responses and Survival Outcomes in Younger Patients (<60 Years Old) Compared to Older Patients (≥60 Years Old) with Acute Myeloid Leukemia

Dasom Lee, MD, Hannah H Asghari, MD, Yehuda E. Deutsch, MD, Onyee Chan, MD, Eric Padron, MD, Andrew T Kuykendall, MD, Alan F. List, MD, Rami S. Komrokji, MD, Hugo F. Fernandez, MD, Jeffrey E. Lancet, MD, David A Sallman, MD, Kendra L. Sweet, MD, Chetasi Talati, MD

Blood (2019) 134 (Supplement_1): 3894.

https://doi.org/10.1182/blood-2019-127701

Published: 2019

Journal Articles

Hypomethylating Agent and Venetoclax Combination Yields Comparable Outcomes to CPX-351 in Newly Diagnosed Acute Myeloid Leukemia

Hannah Asghari, MD, Dasom Lee, MD, Yehuda E. Deutsch, MD, Onyee Chan, MD, Najla Al Ali, M.Sc, Stephanie Boisclair, MD, Constance Terrell, PharmD, BCOP, Eric Padron, MD, Andrew T Kuykendall, MD, Alan F. List, MD, Hugo F. Fernandez, MD, Jeffrey E. Lancet, MD, David A Sallman, MD, Rami S. Komrokji, MD, Kendra L. Sweet, MD, Chetasi Talati, MD

Blood (2019) 134 (Supplement_1): 3895.

https://doi.org/10.1182/blood-2019-130379

Published: 2019

Journal Articles

Safety and Efficacy of Midostaurin in Combination with High-Dose Daunorubicin in 7+3 Induction for Acute Myeloid Leukemia with FLT3 Mutation

Yehuda E. Deutsch, MD, Robert Wilkinson, PharmD, Amanda Brahim, PharmD, Stephanie Boisclair, MD, Jose Sandoval-Sus, MD, Annie Kuehnel, APRN, Terrence J Bradley, MD, Chetasi Talati, MD, Ellen Madarang, PharmD, Jillian Lykon, PharmD, Justin M. Watts, MD, David A Sallman, MD, Kendra L. Sweet, MD, Jeffrey E. Lancet, MD, Hugo F. Fernandez, MD

Blood (2019) 134 (Supplement_1): 3896.

https://doi.org/10.1182/blood-2019-129331

Published: 2019

Journal Articles

Outcomes of Hematopoietic Cell Transplantation in Acute Promyelocytic Leukemia - a Single Institution Experience

Hamza Hashmi, MD, Jeffrey Lancet, MD, Asmita Mishra, MD, Kendra L. Sweet, MD, Rami S. Komrokji, MD, Hugo F. Fernandez, MD, Lia Perez, MD, Farhad Khimani, MD, Michael Nieder, MD, Hany Elmariah, MD MS, Joseph Pidala, MD, Nelli Bejanyan, MD, Alan F. List, MD, Claudio Anasetti, MD, Taiga Nishihori, MD

Blood (2019) 134 (Supplement_1): 5739.

https://doi.org/10.1182/blood-2019-128985

Published: 2019

Journal Articles

Genomic Landscape Impacts Induction Outcome with CPX-351 in Patients with Acute Myeloid Leukemia

Chetasi Talati, MD, Aaron D Goldberg, MD PhD, Pinkal Desai, MD MPH, Onyee Chan, MD, Christopher Famulare, MS, Rami S. Komrokji, MD, Andrew T Kuykendall, MD, Hugo F. Fernandez, MD, Yehuda E. Deutsch, MD, Eric Padron, MD, Alan F. List, MD, Jeffrey E. Lancet, MD, Gail J. Roboz, MD, Martin S. Tallman, MD, David A Sallman, MD, Kendra L. Sweet, MD

Blood (2018) 132 (Supplement 1): 2741.

https://doi.org/10.1182/blood-2018-99-117412

Published: 2018

Journal Articles

Safety and Feasibility of Outpatient Liposomal Daunorubicin and Cytarabine (Vyxeos) Induction and Management in Patients with Secondary AML

Yehuda E. Deutsch, MD, Justin T Presutto, PharmD, MBA, Amanda Brahim, Pharm.D., Jyotishankar Raychaudhuri, MD, Marco Andres Ruiz, MD, Jose Sandoval-Sus, MD, Hugo F. Fernandez, MD

Blood (2018) 132 (Supplement 1): 3559.

https://doi.org/10.1182/blood-2018-99-115682

Published: 2018

Journal Articles

Radius: A Phase 2 Randomized Trial Investigating Standard of Care ± Midostaurin after Allogeneic Stem Cell Transplant in FLT3 -ITD-Mutated AML

Richard Thomas T. Maziarz, MD, Mrinal M. Patnaik, MDMBBS, Bart L Scott, MD, Sanjay R. Mohan, MD MSCI, Abhinav Deol, MD, Scott D. Rowley, MD, Dennis Kim, MD, Kelly Haines, Gaetano J Bonifacio, MD, Patrice Rine, Das Purkayastha, Hugo F. Fernandez, MD

Blood (2018) 132 (Supplement 1): 662.

https://doi.org/10.1182/blood-2018-99-113582

Published: 2018

Journal Articles

Event-Free Survival As a Surrogate Endpoint for Overall Survival in Previously Untreated Acute Myeloid Leukemia: An Individual Patient-Level Analysis of Multiple Randomized Trials (Alliance A151614)

Jun Yin, PhD, Geoffrey L. Uy, MD, Betsy Laplant, MS, Elizabeth Storrick, Guido Marcucci, Hugo F. Fernandez, MD, Zhuoxin Sun, PhD, Mark R. Litzow, MD, Megan Othus, PhD, Frederick R. Appelbaum, MD, Richard A. Larson, MD, Richard M. Stone, MD, Sumithra J Mandrekar, PhD

Blood (2018) 132 (Supplement 1): 1386.

https://doi.org/10.1182/blood-2018-99-113902

Published: 2018

Journal Articles

A Phase II Trial Evaluating the Use of the Histone Deacetylase Inhibitor Panobinostat for Graft-Versus-Host Disease (GVHD) Prevention

Lia Perez, MD, Hugo F. Fernandez, MD, Farhad Khimani, MBBS, Ernesto Ayala, MD, Mohamed A Kharfan-Dabaja, MD, Asmita Mishra, MD, Leonel Ochoa, MD, Brian C. Betts, MD, Joseph Pidala, MD PhD, Claudio Anasetti, MD

Blood (2017) 130 (Supplement 1): 1985.

https://doi.org/10.1182/blood.V130.Suppl_1.1985.1985

Published: 2017

Journal Articles

Posttransplant feasibility study of nilotinib prophylaxis for high-risk Philadelphia chromosome positive leukemia

Paul A. Carpenter, Laura Johnston, Hugo F. Fernandez, Jerald P. Radich, Michael J. Mauro, Mary E. D. Flowers, Paul J. Martin, Theodore A. Gooley

Blood (2017) 130 (9): 1170–1172.

https://doi.org/10.1182/blood-2017-03-771121

Published: 2017

Includes: Supplemental data

Journal Articles

Fludarabine and Melphalan Results in Fewer Relapses Compared to Fludarabine and Targeted Busulfan in Patients Receiving Reduced Intensity Conditioning for AML and MDS

Ryan James Caddell, PharmD, Braydon Schaible, MPH, Zhenjun Ma, PhD, Elizabeth Dimaggio, PharmD, BCOP, Rebecca Tombleson, PharmD, BCOP, Claudio Anasetti, MD, Ernesto Ayala, MD, Brian C. Betts, MD, Mohamed A. Kharfan-Dabaja, MD, Frederick L. Locke, MD, Taiga Nishihori, MD, Joseph A. Pidala, MD, Hugo F. Fernandez, MD, Asmita Mishra, MD

Blood (2016) 128 (22): 3486.

https://doi.org/10.1182/blood.V128.22.3486.3486

Published: 2016

NARROW

DNA polymerase θ protects leukemia cells from metabolically induced DNA damage

DNA Polymerase Theta Protects Leukemia Cells from Metabolic-Induced DNA Damage

Sirolimus Results in Similar Outcomes to Tacrolimus for Gvhd Prophylaxis after Haploidentical Peripheral Blood Stem Cell Transplantation with Post-Transplant Cyclophosphamide

Patients with AML Who Achieve Long Term Complete Remission Do Not Have a Normal Life Expectancy When Compared to the General Population. Analysis of 3,012 Patients Enrolled on 9 Consecutive ECOG-ACRIN Trials

Phase II Trial of Eprenetapopt (APR-246) in Combination with Azacitidine (AZA) As Maintenance Therapy for TP53 Mutated AML or MDS Following Allogeneic Stem Cell Transplantation (SCT)

TET2 and DNMT3A Mutations Exert Divergent Effects on DNA Repair and Sensitivity of Leukemia Cells to PARP Inhibitors

Outcomes of Patients with Relapsed or Refractory Acute Myeloid Leukemia Receiving Hypomethylating Agent and Venetoclax

Hypomethylating Agent and Venetoclax Combination Therapy Yields Superior Outcomes When Compared to Hypomethylating Agent Monotherapy in Patients ≥70 Years with Acute Myeloid Leukemia

Comparison of Overall Responses after Standard Induction with High Dose Daunorubicin Versus Standard Dose Daunorubicin with Gemtuzumab Ozogamicin in Favorable Risk Acute Myeloid Leukemia

CPX-351 As Induction Chemotherapy Yields Similar Responses and Survival Outcomes in Younger Patients (<60 Years Old) Compared to Older Patients (≥60 Years Old) with Acute Myeloid Leukemia

Hypomethylating Agent and Venetoclax Combination Yields Comparable Outcomes to CPX-351 in Newly Diagnosed Acute Myeloid Leukemia

Safety and Efficacy of Midostaurin in Combination with High-Dose Daunorubicin in 7+3 Induction for Acute Myeloid Leukemia with FLT3 Mutation

Outcomes of Hematopoietic Cell Transplantation in Acute Promyelocytic Leukemia - a Single Institution Experience

Genomic Landscape Impacts Induction Outcome with CPX-351 in Patients with Acute Myeloid Leukemia

Safety and Feasibility of Outpatient Liposomal Daunorubicin and Cytarabine (Vyxeos) Induction and Management in Patients with Secondary AML

Radius: A Phase 2 Randomized Trial Investigating Standard of Care ± Midostaurin after Allogeneic Stem Cell Transplant in FLT3 -ITD-Mutated AML

Event-Free Survival As a Surrogate Endpoint for Overall Survival in Previously Untreated Acute Myeloid Leukemia: An Individual Patient-Level Analysis of Multiple Randomized Trials (Alliance A151614)

A Phase II Trial Evaluating the Use of the Histone Deacetylase Inhibitor Panobinostat for Graft-Versus-Host Disease (GVHD) Prevention

Posttransplant feasibility study of nilotinib prophylaxis for high-risk Philadelphia chromosome positive leukemia

Fludarabine and Melphalan Results in Fewer Relapses Compared to Fludarabine and Targeted Busulfan in Patients Receiving Reduced Intensity Conditioning for AML and MDS

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only